THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
Exhibit 4.2
THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of August 25, 2022, by and among RayzeBio, Inc., a Delaware corporation (the “Company”) and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
RECITALS:
WHEREAS, the Company and certain of the Investors (the “Existing Investors”) and certain other stockholders of the Company are parties to that certain Second Amended and Restated Investors’ Rights Agreement, dated June 8, 2021 (the “Prior Agreement”).
WHEREAS, pursuant to Section 6.6 of the Prior Agreement and subject to certain specified exceptions, any term of the Prior Agreement may be amended and the observance of any term of the Prior Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) with the written consent of the Company and the holders of a majority of the Registrable Securities (as defined in the Prior Agreement) then outstanding, which majority shall include (i) the holders of a majority of the Common Stock issuable or issued upon conversion of the Series A Preferred Stock, (ii) the holders of a majority of the Common Stock issuable or issued upon conversion of the Series B Preferred Stock and (iii) the holders of a majority of the Common Stock issuable or issued upon conversion of the Series C Preferred Stock (the “Requisite Existing Investors”).
WHEREAS, the Company and certain of the Investors (the “Participating Investors”) are parties to the Series D Preferred Stock Purchase Agreement of even date herewith (as may be amended from time to time, the “Purchase Agreement”).
WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to induce the Participating Investors to invest funds in the Company pursuant to the Purchase Agreement, the Company and the undersigned Existing Investors, constituting the Requisite Existing Investors, desire to amend and restate and supersede the Prior Agreement in its entirety as set forth herein and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement.
AGREEMENT
NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the undersigned Existing Investors, constituting the Requisite Existing Investors, hereby agree that the Prior Agreement shall be amended and restated and superseded in its entirety by this Agreement, and the parties to this Agreement further agree as follows:
1. Definitions. For purposes of this Agreement:
1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any equityholder, partner (including any general or managing partner), member, managing member, officer, director or trustee of such Person, or any venture capital fund, other investment fund, registered investment company, partner or affiliated partnership now or hereafter existing that is controlled or managed by one or more general or managing partners, managing members or investment advisers of, or shares the same management company or investment adviser with, such Person (or is managed by any Person that is an Affiliate of any such management company or managing (general) partner), or any trust for the benefit of any of the foregoing.
1.2 “Board of Directors” means the board of directors of the Company.
1.3 “Certificate of Incorporation” means the Company’s Fourth Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time.
1.4 “Common Stock” means shares of the Company’s common stock, par value $0.0001 per share.
1.5 “Competitor” means a Person engaged, directly or indirectly (including through any partnership, limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in the business of the Company, but shall not include any financial investment firm or collective investment vehicle that, together with its Affiliates, holds less than 20% of the outstanding equity of any Competitor and does not, nor do any of its Affiliates, have a right to designate any members of the board of directors of any Competitor; provided, that venBio Global Strategic Fund III, L.P. (together with its Affiliates, “venBio”), Versant Venture Capital VII, L.P. (together with its Affiliates, “Versant”), Samsara BioCapital, L.P. (together with its Affiliates, “Samsara”), Venrock Healthcare Capital Partners III, L.P. (together with its Affiliates, “Venrock”), OrbiMed Private Investments VIII, LP (together with its Affiliates, “OrbiMed”), RYZB Holdings Limited (together with its Affiliates, “RYZB”), Xxxxxxx Capital Master Fund Ltd. (together with its Affiliates, “Xxxxxxx”), Xxxxx Capital Life Sciences Pulse Fund II, L.P. (“Sands Capital”), Redmile Biopharma Investments II, L.P. (together with its Affiliates, “Redmile”), Perceptive Life Sciences Master Fund, Ltd. (together with its Affiliates, “Perceptive”), Vivo Opportunity Fund, L.P. (together with its Affiliates, “Vivo”), Acuta Capital Partners, LLC (together with its Affiliates, “Acuta”), Deerfield Partners, L.P. (together with its Affiliates, “Deerfield”), TCG Crossover Fund I, L.P. (together with its Affiliates, “TCGx”), Alexandria Venture Investments, LLC (together with its Affiliates, “AVI”), Viking Global Opportunities Illiquid Investments Sub-Master LP or Viking Global Opportunities Drawdown (Aggregator) LP (together with their respective Affiliates, “Viking”), Sofinnova Management X, L.P. (together with its Affiliates, “Sofinnova”) and Wellington Biomedical Innovation Master Investors (Cayman) II L.P. (together with its Affiliates, “Wellington”), shall not be deemed to be a Competitor.
1.6 “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law.
1.7 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants.
1.8 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
1.9 “Excluded Registration” means (i) a registration relating to the sale or grant of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered.
2.
1.10 “FOIA Party” means a Person that, in the reasonable determination of the Board of Directors, may be subject to, and thereby required to disclose non-public information furnished by or relating to the Company under, the Freedom of Information Act, 5 U.S.C. 552 (“FOIA”), any state public records access law, any state or other jurisdiction’s laws similar in intent or effect to FOIA, or any other similar statutory or regulatory requirement.
1.11 “Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC.
1.12 “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits forward incorporation of substantial information by reference to other documents filed by the Company with the SEC.
1.13 “GAAP” means generally accepted accounting principles in the United States as in effect from time to time.
1.14 “Holder” means any holder of Registrable Securities who is a party to this Agreement.
1.15 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, domestic partner, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including, adoptive relationships, of a natural person referred to herein.
1.16 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.
1.17 “IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act.
1.18 “Major Investor” means any Investor that, individually or together with such Investor’s Affiliates, holds at least 5,000,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof).
1.19 “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities.
1.20 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.
1.21 “Preferred Stock” means, collectively, shares of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock.
1.22 “Preferred Director” means each of the Series A Directors, the Series B Director and the Series D Director.
1.23 “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Investors; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clause (i) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 6.1 and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Section 2.13 of this Agreement.
3.
1.24 “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities.
1.25 “Requisite Holders” shall mean the Holders of a majority of the Registrable Securities then outstanding, which majority shall include (i) the holders of a majority of the Common Stock issuable or issued upon conversion of the Series A Preferred Stock, (ii) the holders of a majority of the Common Stock issuable or issued upon conversion of the Series B Preferred Stock, (iii) the holders of a majority of the Common Stock issuable or issued upon conversion of the Series C Preferred Stock and (iv) the holders of 60% of the Common Stock issuable or issued upon conversion of the Series D Preferred Stock (the “Requisite Series D Holders”).
1.26 “Restricted Securities” means the securities of the Company required to be notated with the legend set forth in Section 2.12(b) hereof.
1.27 “SEC” means the Securities and Exchange Commission.
1.28 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act.
1.29 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.
1.30 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
1.31 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Section 2.6.
1.32 “Series A Director” means any director of the Company that the holders of record of the Series A Preferred Stock are entitled to elect, exclusively and as a separate class, pursuant to the Certificate of Incorporation.
1.33 “Series B Director” means any director of the Company that the holders of record of the Series B Preferred Stock are entitled to elect, exclusively and as a separate class, pursuant to the Certificate of Incorporation.
1.34 “Series D Director” means any director of the Company that the holders of record of the Series D Preferred Stock are entitled to elect, exclusively and as a separate class, pursuant to the Certificate of Incorporation.
1.35 “Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.0001 per share.
1.36 “Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.0001 per share.
1.37 “Series C Preferred Stock” means shares of the Company’s Series C Preferred Stock, par value $0.0001 per share.
4.
1.38 “Series D Preferred Stock” means shares of the Company’s Series D Preferred Stock, par value $0.0001 per share.
2. Registration Rights. The Company covenants and agrees as follows:
2.1 Demand Registration.
(a) Form S-1 Demand. If at any time after 180 days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of 50% of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement covering the registration of Registrable Securities with an anticipated aggregate offering price, net of Selling Expenses, of at least $15 million, then the Company shall (x) within 10 days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within 60 days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and 2.3.
(b) Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $3 million, then the Company shall (i) within 10 days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within 45 days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and 2.3.
(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board of Directors it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than 60 days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any 12-month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such 60-day period other than pursuant to a registration relating to the sale or grant of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered.
5.
(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(a): (i) during the period that is 60 days before the Company’s good faith estimate of the date of filing of, and ending on a date that is 180 days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two registration pursuant to Section 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b): (i) during the period that is 30 days before the Company’s good faith estimate of the date of filing of, and ending on a date that is 90 days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Section 2.1(b) within the 12 month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Section 2.1(d); provided, that if such withdrawal is during a period the Company has deferred taking action pursuant to Section 2.1(c), then the Initiating Holders may withdraw their request for registration and such registration will not be counted as “effected” for purposes of this Section 2.1(d).
2.2 Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within 20 days after such notice is given by the Company, the Company shall, subject to the provisions of Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Section 2.6.
2.3 Underwriting Requirements.
(a) If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Board of Directors, with the approval of three of the Preferred Directors (or, if fewer, such number of Preferred Directors as there are then serving), and shall be reasonably acceptable to a majority in interest of the Initiating Holders. Notwithstanding anything to the contrary herein and for the avoidance of doubt, all matters requiring the approval of three Preferred Directors in this Investors’ Rights Agreement shall (i) in the event of a vacancy of a seat otherwise filled by a Preferred Director, only require the approval of two Preferred Directors, which approval must include the Series D Director or (ii) in the event of a vacancy of the Series D Director seat, only require the approval of two Preferred Directors. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Section 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities
6.
owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares.
(b) In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below 20% of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering. For purposes of the provision in this Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence.
(c) For purposes of Section 2.1, a registration shall not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Section 2.3(a), fewer than 50% of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually included.
2.4 Obligations of the Company. Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible:
(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to 120 days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such 120-day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such 120-day period shall be extended for up to 60 days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold;
7.
(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement;
(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities;
(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act;
(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering;
(f) use its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed;
(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration;
(h) promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith;
(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and
(j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus.
In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its xxxxxxx xxxxxxx policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.
2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities.
8.
2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed $50,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Requisite Holders agree to forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf.
2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2.
2.8 Indemnification. If any Registrable Securities are included in a registration statement under this Section 2:
(a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration.
(b) To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Section 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Xxxxxx.
9.
(c) Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.8.
(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Section 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder.
(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control;
(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this Agreement.
10.
2.9 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall:
(a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO;
(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and
(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after 90 days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form).
2.10 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent of the Requisite Holders, enter into any agreement with any holder or prospective holder of any securities of the Company that would (i) allow such holder or prospective holder the right to include securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of Registrable Securities of the Holders that are included or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder; provided that this limitation shall not apply to Registrable Securities acquired by any additional Investor that becomes a party to this Agreement in accordance with Section 6.9.
2.11 “Market Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company of shares of its Common Stock or any other equity securities under the Securities Act on a registration statement on Form S-1, and ending on the date specified by the Company and the managing underwriter (such period not to exceed 180 days in the case of the IPO), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held by such Holder immediately before the effective date of the registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Section 2.11 shall apply only to the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, the sale of Registrable Securities sold pursuant to the registration statement for the IPO, the sale of any shares purchased in connection with the IPO, the sale of any shares purchased subsequent to the IPO in the open market, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the Immediate Family Member of the Holder, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers, directors and stockholders individually owning more than
11.
1% of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are subject to the same restrictions. The underwriters in connection with such registration are intended third-party beneficiaries of this Section 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Company stockholders that are subject to such agreements, based on the number of shares subject to such agreements.
2.12 Restrictions on Transfer.
(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. For the avoidance of doubt, a customary arrangement in connection with the deposit of Registrable Securities in a non-margin custodial account shall not be deemed a sale, transfer or pledge for purposes of this Agreement so long as such Registrable Securities are in certificated form (it being understood that the Company may require the exchange of any such certificated securities for book-entry securities upon the IPO). Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the IPO, SEC Rule 144, in each case, to be bound by the terms of this Agreement.
(b) Each certificate, instrument, or book entry representing (i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of Section 2.12(c)) be notated with a legend substantially in the following form:
THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.
The Holders consent to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12.
(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction or following the IPO, the transfer is made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer; provided that no such notice shall be required in connection if the intended sale, pledge or transfer complies with SEC Rule 144. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by
12.
the Company, shall be accompanied at such Xxxxxx’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder; provided that with respect to transfers under the foregoing clause (y), each transferee agrees in writing to be subject to the terms of this Section 2.12. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Section 2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act.
2.13 Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Sections 2.1 or 2.2 shall terminate upon the earliest to occur of:
(a) the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation;
(b) such time after consummation of the IPO (or other effective registration of the Company’s securities pursuant to Section 12(b) of the Exchange Act) as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares without limitation during a three-month period without registration;
(c) the fifth anniversary of the IPO or other effective registration of the Company’s securities pursuant to Section 12(b) of the Exchange Act.
3. Information and Inspection Rights.
3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the Board of Directors has not reasonably determined that such Major Investor is a Competitor of the Company:
(a) as soon as practicable, but in any event within 120 days after the end of each fiscal year of the Company, (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all such financial statements audited and certified by independent public accountants of nationally recognized standing selected by the Company;
(b) as soon as practicable, but in any event within 45 days after the end of each quarter of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP);
13.
(c) as soon as practicable, but in any event within 45 days after the end of each quarter of each fiscal year of the Company, (i) a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company, and (ii) the Company’s most recent 409(a) valuation report; and
(d) as soon as practicable, but in any event 30 days before the end of each fiscal year, a budget and business plan for the next fiscal year approved by the Board of Directors, including three of the Preferred Directors (or, if fewer, such number of Preferred Directors as there are then serving) (collectively, the “Budget”), prepared on a quarterly basis, including balance sheets, income statements, and statements of cash flow for such fiscal quarter and, promptly after prepared, any other budgets or revised budgets prepared by the Company.
If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries.
Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this Section 3.1 during the period starting with the date 60 days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective.
3.2 Inspection. The Company shall permit each Major Investor, provided that the Board of Directors has not reasonably determined that such Major Investor is a Competitor of the Company, at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.
3.3 Observer Rights. The Company shall invite (i) a person designated by Xxxxxxx, as long as Samsara owns not less than twenty-five percent (25%) of the shares of the Series A Preferred Stock that it originally purchased (or an equivalent amount of Common Stock issued upon conversion thereof), (ii) a person designated by Sofinnova, as long as Sofinnova (x) owns not less than twenty-five percent (25%) of the shares of the Series D Preferred Stock that it originally purchased (or an equivalent amount of Common Stock issued upon conversion thereof) and (y) does not have a representative on the Board of Directors, (iii) a person designated by Viking, as long as Viking owns not less than twenty-five percent (25%) of the shares of the Series D Preferred Stock that it originally purchased (or an equivalent amount of Common Stock issued upon conversion thereof) and (iv) a person designated by Wellington, as long as Wellington owns not less than twenty-five percent (25%) of the shares of the Series D Preferred Stock that it originally purchased (or an equivalent amount of Common Stock issued upon conversion thereof), to attend all meetings of the Board of Directors (and all committees of the Board of Directors) in a nonvoting observer capacity and, in this respect, shall give such representatives copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors; provided, however, that such representatives shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude such representatives from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a Competitor of the Company.
14.
3.4 Termination of Information and Observer Rights. The covenants set forth in Section 3.1, Section 3.2 and Section 3.3 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO or other effective registration of the Company’s securities pursuant to Section 12(b) of the Exchange Act, or (ii) upon the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first.
3.5 Confidentiality.
(a) Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company or in connection with evaluating investment opportunities in the ordinary course of business) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.5 by such Investor), (b) is or has been independently developed or conceived by such Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to such Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Section 3.5; (iii) to any existing or prospective Affiliate, partner, limited partner (or partner of a partner), member, stockholder, or wholly owned subsidiary of such Investor, or any subsequent partnership under common investment management in the ordinary course of business, as part of such Investor’s normal reporting or review procedure, or in connection with such Investor’s or its Affiliates’ normal fundraising, marketing, informational or reporting activities, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information, and provided further that such Person is not a Competitor; or (iv) as may otherwise be required by law, regulation, rule, court order or subpoena, provided that such Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure.
(b) In the event that any Affiliate of an Investor becomes a Competitor, or any Investor or any of its Affiliates becomes a FOIA Party, such Investor shall so inform the Company and, as a condition to the disclosure thereafter of any confidential information to such Investor and/or Affiliate, such Investor and/or Affiliate and the Company shall negotiate and enter into a supplemental confidentiality agreement, reasonably satisfactory to the Company. In the event that the Board of Directors determines in good faith that an Affiliate of an Investor has become a Competitor or an Investor or its Affiliate has become a FOIA Party, the Company shall so inform such Investor and, as a condition to the disclosure thereafter of any confidential information to such Investor and/or Affiliate, such Investor and/or Affiliate and the Company shall negotiate and enter into a supplemental confidentiality agreement, reasonably satisfactory to the Company.
4. Rights to Future Stock Issuances.
4.1 Right of First Offer. Subject to the terms and conditions of this Section 4.1 and applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Investor. An Investor shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems appropriate, among (i) itself, (ii) its Affiliates and (iii) its beneficial interest holders, such as limited partners, members or any other Person having “beneficial ownership,” as such term is defined in Rule 13d-3 promulgated under the Exchange
15.
Act, of such Investor (“Investor Beneficial Owners”); provided that each such Affiliate or Investor Beneficial Owner (x) is not a Competitor, unless such party’s purchase of New Securities is otherwise consented to by the Board of Directors, (y) agrees to enter into this Agreement and each of the Voting Agreement and Right of First Refusal and Co-Sale Agreement of even date herewith among the Company, the Investors and the other parties named therein, as an “Investor” under each such agreement (provided that any Competitor shall not be entitled to any rights as a Major Investor under Sections 3.1 and 3.2 hereof or as an Investor under this Section 4.1), and (z) agrees to purchase at least such number of New Securities as are allocable hereunder to the Investor holding the fewest number of Preferred Stock and any other Derivative Securities.
(a) The Company shall give notice (the “Offer Notice”) to each Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities.
(b) By notification to the Company within 20 days after the Offer Notice is given, each Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Investor (including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Investor) bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and any other Derivative Securities then outstanding). At the expiration of such 20-day period, the Company shall promptly notify each Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Investor’s failure to do likewise. During the 10-day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Investors were entitled to subscribe but that were not subscribed for by the Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Section 4.1(b) shall occur within the later of 90 days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Section 4.1(c).
(c) If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Section 4.1(b), the Company may, during the 90-day period following the expiration of the periods provided in Section 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within 30 days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investors in accordance with this Section 4.1.
(d) The right of first offer in this Section 4.1 shall not be applicable to (i) Exempted Securities (as defined in the Certificate of Incorporation) and (ii) shares of Common Stock issued in the IPO.
4.2 Termination. The covenants set forth in Section 4.1 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO or other effective registration of the Company’s securities pursuant to Section 12(b) of the Exchange Act, or (ii) upon the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first.
16.
5. Additional Covenants.
5.1 Insurance. The Company shall maintain, from financially sound and reputable insurers, Directors and Officers liability insurance in an amount and on terms and conditions satisfactory to the Board of Directors, including three of the Preferred Directors (or, if fewer, such number of Preferred Directors as there are then serving), and will use commercially reasonable efforts to cause such insurance policies to be maintained until such time as the Board of Directors, including three of the Preferred Directors (or, if fewer, such number of Preferred Directors as there are then serving), determines that such insurance should be discontinued. The policy will not be cancelable by the Company without prior approval by the Board of Directors, including three of the Preferred Directors (or, if fewer, such number of Preferred Directors as there are then serving). Notwithstanding any other provision of this Section 5.1 to the contrary, for so long as a Preferred Director is serving on the Board of Directors, the Company shall not cease to maintain a Directors and Officers liability insurance policy in an amount of at least three million unless approved by three of the Preferred Directors (or, if fewer, such number of Preferred Directors as there are then serving).
5.2 Employee Agreements. The Company will cause (i) each Person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement; and (ii) the Key Persons (as defined in the Purchase Agreement) to enter into a one year non-solicitation agreement, substantially in the form approved by the Board of Directors.
5.3 Employee Stock. Unless otherwise approved by the Board of Directors, which approval must include the affirmative vote of three of the Preferred Directors (or, if fewer, such number of Preferred Directors as there are then serving), all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four year period, with the first 25% of such shares vesting following 12 months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following 36 months, and (ii) a market stand-off provision substantially similar to that in Section 2.11. Without the prior approval by the Board of Directors, the Company shall not amend, modify, terminate, waive or otherwise alter, in whole or in part, any stock purchase, stock restriction or option agreement with any existing employee or service provider if such amendment would cause it to be inconsistent with this Section 5.3. In addition, unless otherwise approved by the Board of Directors, including three of the Preferred Directors (or, if fewer, such number of Preferred Directors as there are then serving), the Company shall retain (and not waive) a “right of first refusal” on employee transfers until the IPO and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock.
5.4 Matters Requiring Investor Director Approval. So long as the holders of Preferred Stock are entitled to elect Preferred Directors, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board of Directors, which approval must include the affirmative vote of three of the Preferred Directors (or, if fewer, such number of Preferred Directors as there are then serving):
(a) make, or permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company;
(b) make, or permit any subsidiary to make, any loan or advance to any Person, including, without limitation, any employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board of Directors;
17.
(c) guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness except for trade accounts of the Company or any subsidiary arising in the ordinary course of business;
(d) make any investment inconsistent with any investment policy approved by the Board of Directors;
(e) incur any aggregate indebtedness in excess of $100,000 that is not already included in a budget approved by the Board of Directors, other than trade credit incurred in the ordinary course of business;
(f) otherwise enter into or be a party to any transaction with any director, officer, or employee of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, including without limitation any “management bonus” or similar plan providing payments to employees in connection with a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, except for transactions contemplated by this Agreement and the Purchase Agreement; transactions resulting in payments to or by the Company in an aggregate amount less than $100,000 per year; or transactions made in the ordinary course of business and pursuant to reasonable requirements of the Company’s business and upon fair and reasonable terms that are approved by a majority of the Board of Directors;
(g) hire, terminate, or change the compensation of the executive officers, including approving any option grants or stock awards to executive officers;
(h) change the principal business of the Company, enter new lines of business, or exit the current line of business;
(i) sell, assign, license, pledge, or encumber material technology or intellectual property, other than licenses granted in the ordinary course of business; or
(j) enter into any corporate strategic relationship involving the payment, contribution, or assignment by the Company or to the Company of money or assets greater than $100,000.
5.5 Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, including the affirmative vote of three of the Preferred Directors (or, if fewer, such number of Preferred Directors as there are then serving), the Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the nonemployee directors for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors and other meetings or events attended on behalf of the Company at the Company’s request. Each committee established by the Board of Directors shall include at least three of the Preferred Directors (or, if fewer, such number of Preferred Directors as there are then serving), unless service on such committee is waived or deferred at the sole discretion of the Preferred Directors. The Company shall enter into an indemnification agreement with any future Preferred Director.
5.6 Indemnification Matters. The Company hereby acknowledges that one or more of the directors nominated to serve on the Board of Directors by the Investors (each an “Investor Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of their Affiliates (collectively, the “Investor Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Investor Director are primary and any obligation of the Investor Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Investor Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Investor Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Investor Director to the extent legally permitted and as required by the Company’s Certificate of Incorporation or Bylaws of the
18.
Company (or any agreement between the Company and such Investor Director), without regard to any rights such Investor Director may have against the Investor Indemnitors, and (c) that it irrevocably waives, relinquishes and releases the Investor Indemnitors from any and all claims against the Investor Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Investor Indemnitors on behalf of any such Investor Director with respect to any claim for which such Investor Director has sought indemnification from the Company shall affect the foregoing and the Investor Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Investor Director against the Company. The Investor Directors and the Investor Indemnitors are intended third-party beneficiaries of this Subsection 5.6 and shall have the right, power and authority to enforce the provisions of this Subsection 5.6 as though they were a party to this Agreement.
5.7 Right to Conduct Activities. The Company hereby agrees and acknowledges that venBio, Samsara, Versant, Venrock, OrbiMed, Redmile, Viking, Perceptive, Vivo, Acuta, Deerfield, TCGx, Sofinnova, AVI, Xxxxxxx, Xxxxx Capital, Wellington and RYZB each is a professional investment organization, and as such reviews the business plans and related proprietary information of many enterprises, some of which may compete directly or indirectly with the Company’s business (as currently conducted or as currently propose to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, venBio, Samsara, Versant, Venrock, OrbiMed, Redmile, Viking, Perceptive, Vivo, Acuta, Deerfield, TCGx, Sofinnova, AVI, Xxxxxxx, Xxxxx Capital, Wellington and RYZB shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by venBio, Samsara, Versant, Venrock, OrbiMed, Redmile, Viking, Perceptive, Vivo, Acuta, Deerfield, TCGx, Sofinnova, AVI, Xxxxxxx, Xxxxx Capital, Wellington or RYZB in any entity competitive with the Company, or (ii) actions taken by any partner, officer, employee or other representative of venBio, Samsara, Versant, Venrock, OrbiMed, Redmile, Viking, Perceptive, Vivo, Acuta, Deerfield, TCGx, Sofinnova, AVI, Xxxxxxx, Xxxxx Capital, Wellington or RYZB to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. Nothing in this Agreement shall preclude, create an obligation or duty, or in any way restrict venBio, Samsara, Versant, Venrock, OrbiMed, Redmile, Viking, Perceptive, Vivo, Acuta, Deerfield, TCGx, Sofinnova, AVI, Xxxxxxx, Xxxxx Capital, Wellington and RYZB from evaluating or purchasing securities, including publicly traded securities, of a particular enterprise, or investing or participating in any particular enterprise, whether or not such enterprise has products or services which compete with those of the Company.
5.8 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, the Certificate of Incorporation, or elsewhere, as the case may be.
5.9 Publicity. The Company hereby agrees and acknowledges that it shall not use the name of RYZB, venBio, Versant, Samsara, OrbiMed, Redmile, Viking, Perceptive, Vivo, Acuta, Deerfield, Xxxxxxx, TCGx, Sands Capital, Wellington, AVI or Venrock in any trade publication, marketing materials or otherwise to the general public, in each case without the prior written consent of such Investor, which consent may be withheld in its sole discretion; provided, that (i) the parties anticipate that there will be a mutually-agreed press release announcing the closing of the transactions contemplated in the Purchase Agreement (provided that none of RYZB, Redmile, Wellington or Viking shall be named or referenced in the press release, without such Investor’s prior written consent); (ii) following the public announcement contemplated in clause (i), the Company may confirm that venBio,
19.
Versant, Samsara, OrbiMed, Perceptive, Vivo, Acuta, Deerfield, Xxxxxxx, TCGx, Sands Capital, Wellington, AVI and Venrock are investors in the Company (but not the amount or terms thereof) in a form of disclosure that has been previously approved by such Investors; and (iii) the Company may list or disclose the names of venBio, Versant, Samsara, OrbiMed, Perceptive, Vivo, Acuta, Deerfield, Xxxxxxx, TCGx, Wellington, Sands Capital, AVI and Venrock when identifying such Investor on the Company’s website or in Company presentations. Without an Investor’s prior written consent, none of the Company, its subsidiaries, any other Investor or their respective Affiliates shall use, publish, reproduce, or refer to such Investor, its related parties, controlling persons, or any similar name, trademark or logo in any marketing, advertising, publicity or other similar materials, provided that the Company may disclose the names of the Investor(s) as required by law or regulation, including without limitation in any registration statement filed with the SEC pursuant to the Securities Act, in which case such Investor(s) who are Major Investors shall have the right to review and comment on such disclosure prior to it being disclosed.
5.10 Anti-Harassment Policy. The Company shall, within 90 days following the Closing (as defined in the Purchase Agreement), adopt and thereafter maintain in effect an Anti-Harassment and Discrimination Policy prohibiting discrimination and harassment at the Company. Such policy shall be reviewed and approved by the Board of Directors.
5.11 FCPA. The Company covenants that it shall not (and shall not permit any of its subsidiaries or Affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of value to, directly or indirectly, to any third party, including any Non-U.S. Official (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), in each case, in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company shall promptly notify each Investor if the Company becomes aware of any Enforcement Action (as defined in the Purchase Agreement).
5.12 Participation in IPO. Subject to compliance with applicable securities laws, the Company will use commercially reasonable efforts to cause the managing underwriter(s) of the IPO to allow Investors to submit an indication of interest in the IPO for up to their pro rata ownership interest in the Company at the price per share to the public to be shown in the final prospectus related to the IPO.
5.13 Termination of Covenants. The covenants set forth in this Section 5, except for Section 5.8, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO or other effective registration of the Company’s securities pursuant to Section 12(b) of the Exchange Act, or (ii) upon a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first.
6. Miscellaneous.
6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that (a) is an Affiliate of a Holder; (b) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (c) after such transfer, holds at least 250,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (i) that is an Affiliate or stockholder of a Holder; (ii) who is a Holder’s Immediate Family Member; or (iii) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall, as a condition to the applicable transfer, establish a single attorney-in-fact for the purpose of exercising any rights, receiving
20.
notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein.
6.2 Governing Law. This Agreement shall be governed by the internal law of the State of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware.
6.3 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, the Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement.
6.5 Notices.
(a) All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Section 6.5. If notice is given to the Company, it shall be sent to RayzeBio, Inc., 0000 Xxxxxxxxx Xxxxx, Xxxxx 000, Xxx Xxxxx, XX 00000, Attention: Xxx Song, M.D.; and a copy (which shall not constitute notice) shall also be sent to Xxxxxx LLP, 0000 Xxxxxxxx Xxxx, Xxx Xxxxx, XX 00000, Attention: Xxxxx X. Xxxxxxxxx. If notice is given to Venrock, a copy shall also be given to Xxxxxx Xxxxxxx Xxxxxxxx & Xxxxxx, P.C., 000 Xxxx Xxxx Xxxx, Xxxx Xxxx, XX 00000, Attention: Xxxxx Xxxxxxx and Xxxxxx Xxxxxxxxx; if notice is given to Viking or Sofinnova, a copy shall also be given to Xxxxxxxxx Xxxxxxx Xxxxxx Xxxxxxxxxx Xxxxxxxx & Xxxxxxxxx LLP, 0000 Xxxxxxxx, 00xx Xxxxx, Xxx Xxxx, XX 00000, Attention: Xxxx Xxxxxxx; and if notice is given to Wellington, a copy shall also be given to Xxxxxx Xxxxxx Xxxxxxxxx Xxxx and Xxxx LLP, 00 Xxxxx Xxxxxx, Xxxxxx, XX 00000, Attention: Xxxxx Xxxxx.
(b) Consent to Electronic Notice. Each Investor consents to the delivery of any stockholder notice pursuant to the Delaware General Corporation Law (the “DGCL”), as amended or superseded from time to time, by electronic transmission pursuant to Section 232 of the DGCL (or any successor thereto) at the electronic mail address or the facsimile number set forth below such Investor’s name on the Schedules hereto, as updated from time to time by notice to the Company, or as on the books of the Company. To the extent that any notice given by means of electronic transmission is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected electronic mail address has been provided, and such attempted Electronic Notice shall be ineffective and deemed to not have been given. Each Investor agrees to promptly notify the Company of any change in such stockholder’s electronic mail address, and that failure to do so shall not affect the foregoing.
21.
6.6 Amendments and Waivers. Any term of this Agreement may be amended, modified or terminated and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the Requisite Holders; provided that the Company may in its sole discretion waive compliance with Section 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Section 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, (a) this Agreement may not be amended, modified or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, modification, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms), (b) an amendment, modification, termination to or waiver of Sections 3.1 and 3.2 and any other section of this Agreement applicable to the Major Investors (including this clause (b) of this Section 6.6) shall require only the written consent of the Company and the holders of a majority of the Registrable Securities then outstanding and held by the Major Investors, (c) the provisions of Sections 1.5, 3.3, 5.7 and 5.9 may not be amended, modified, terminated or waived with respect to any Investor without the written consent of such Investor, and (d) Section 3.3 may not be amended, modified, terminated or waived without the consent of Samsara. Notwithstanding the foregoing, Schedule A hereto may be amended by the Company from time to time to add transferees of any Registrable Securities in compliance with the terms of this Agreement without the consent of the other parties; and Schedule A hereto may also be amended by the Company after the date of this Agreement without the consent of the other parties to add information regarding any additional Investor who becomes a party to this Agreement in accordance with Section 6.9. To the extent that any Investor waives, pursuant to Section 6.6 hereof, its right to purchase New Securities pursuant to Section 4 hereof but otherwise participates in such issuance of New Securities (a “Waiving Investor”), then each Investor that has not waived such rights shall retain the right to participate in the issuance of such New Securities (the “Waived Insider Offering”) with such Waiving Investor up to that portion of such New Securities acquired by Investors in such Waived Insider Offering which equals the proportion that the Common Stock then held by such Investor (including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Investor) bears to the total Common Stock of the Company then held by all Investors acquiring New Securities in such Waived Insider Offering (including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Investors. The Company shall give prompt notice of any amendment, modification or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, modification, termination or waiver. Any amendment, modification, termination, or waiver effected in accordance with this Section 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision.
6.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law.
6.8 Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliates may apportion such rights as among themselves in any manner they deem appropriate.
22.
6.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the Company’s Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock or Series D Preferred Stock after the date hereof, any purchaser of such shares of Preferred Stock shall become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder.
6.10 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. Upon the effectiveness of this Agreement, the Prior Agreement shall be deemed amended and restated and superseded in its entirety by this Agreement, and shall be of no further force or effect.
6.11 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Delaware and to the jurisdiction of the U.S. District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Delaware or the U.S. District Court for the District of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.
6.12 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.
[Remainder of Page Intentionally Left Blank]
23.
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| COMPANY: | ||
| RAYZEBIO, INC. | ||
| By: | /s/ Xxx Xxxx | |
| Name: Xxx Xxxx, M.D. | ||
| Title: Chief Executive Officer | ||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTORS: | ||||
| SOFINNOVA VENTURE PARTNERS X, L.P.
By: Sofinnova Management X, L.L.C., its General Xxxxxx | ||||
| By: | /s/ Xxxx Xxxxxx | |||
| Name: | Xxxx Xxxxxx | |||
| Title: | Managing Member | |||
| SOFINNOVA VENTURE PARTNERS XI, L.P.
By: Sofinnova Management XI, L.P., its General Partner | ||||
| By: | Sofinnova Management XI, L.L.C., its General Partner | |||
| By: | /s/ Xxxx Xxxxxx | |||
| Name: | Xxxx Xxxxxx | |||
| Title: | Managing Member | |||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTOR: | ||||
| XXXXXXXXXX BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) II L.P. | ||||
| By: Wellington Management Company LLP, as investment advisor | ||||
| By: | /s/ Xxxxx X. XxXxxxx | |||
| Name: | Xxxxx X. XxXxxxx | |||
| Title: | Managing Director & Counsel | |||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTOR: | ||||
| ABG WTT-RAYZEBIO LIMITED | ||||
| By: | /s/ Wing C Xxx | |||
| Name: | Wing C Xxx | |||
| Title: | Director | |||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTOR: | ||
| SANDS CAPITAL LIFE SCIENCES PULSE FUND II, L.P. | ||
| By: | Sands Capital Life Sciences Pulse Fund II-GP, L.P., its general partner | |
| By: | Sands Capital Life Sciences Pulse Fund II-GP, LLC, its general partner | |
| By: | /s/ Xxxxxxxx Xxxxxxx | |
| Name: Xxxxxxxx Xxxxxxx | ||
| Title: General Counsel | ||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTOR: | ||||
| AL RAYYAN HOLDING LLC | ||||
| By: | /s/ Xxxxx Xx-Xxxxxx | |||
| Name: | Xxxxx Xx-Xxxxxx | |||
| Title: | Director | |||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTOR: | ||||
| XXXXXXX CAPITAL MASTER FUND LTD. | ||||
| By: | /s/ Xxxxxx Xxxxxxx | |||
| Name: | Xxxxxx Xxxxxxx | |||
| Title: | Director | |||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTOR: | ||||
| SOLEUS PRIVATE EQUITY FUND III, L.P.
By: Soleus Private Equity GP III, LLC, its General Partner | ||||
| By: | /s/ Xxxxxx X. Xxxxxxxx | |||
| Name: | Xxxxxx X. Xxxxxxxx | |||
| Title: | Chief Operating Officer | |||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTORS: | ||||
| VENROCK HEALTHCARE CAPITAL PARTNERS EG, L.P. | ||||
| By: | VHCP Management EG, LLC, its general partner | |||
| By: | /s/ Xxxxxx Xxxx | |||
| Name: | Xxxxxx Xxxx | |||
| Title: | Authorized Signatory | |||
| VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P. | ||||
| By: | VHCP Management III, LLC, its general partner | |||
| By: | VR Advisor, LLC, its manager | |||
| By: | /s/ Xxxxxx Xxxx | |||
| Name: | Xxxxxx Xxxx | |||
| Title: | Authorized Signatory | |||
| VHCP CO-INVESTMENT HOLDINGS III, LLC | ||||
| By: | VHCP Management III, LLC, its manager | |||
| By: | VR Advisor, LLC, its manager | |||
| By: | /s/ Xxxxxx Xxxx | |||
| Name: | Xxxxxx Xxxx | |||
| Title: | Authorized Signatory | |||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTORS: | ||||
| ACUTA CAPITAL FUND, LP By: Acuta Capital Partners, LLC Its: General Partner | ||||
| By: | /s/ Xxxxx Xxxxx | |||
| Name: | Xxxxx X. Xxxxx | |||
| Title: | Chief Operating Officer | |||
| ACUTA OPPORTUNITY FUND, LP By: Acuta Capital Partners, LLC Its: General Partner | ||||
| By: | /s/ Xxxxx Xxxxx | |||
| Name: | Xxxxx X. Xxxxx | |||
| Title: | Chief Operating Officer | |||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTOR: | ||
| DEERFIELD PARTNERS, L.P. | ||
| By: Deerfield Mgmt, L.P., General Partner By: X.X. Xxxxx Capital, LLC, General Partner | ||
| /s/ Xxxxx X. Xxxxx | ||
| Name: | Xxxxx X. Xxxxx | |
| Title: | Authorized Signatory | |
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTOR: | ||||
| TCG CROSSOVER FUND I, L.P. | ||||
| By: | TCG Crossover GP I, LLC | |||
| Its General Partner | ||||
| By: | /s/ Xxxx Xx | |||
| Name: | Xxxx Xx | |||
| Title: | Managing Member | |||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTOR: | ||||
| venBio Global Strategic Fund III, L.P. | ||||
| By: | venBio Strategic GP III, L.P. | |||
| Its: | General Partner | |||
| By: | venBio Strategic GP III, Ltd. | |||
| Its: | General Partner | |||
| By: | /s/ Xxxxx Xxxxxxx | |||
| Name: | Xxxxx Xxxxxxx, M.D. | |||
| Title: | Managing Partner | |||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTORS: | ||||
| Versant Venture Capital VII, L.P. | ||||
| By: | Versant Ventures VII GP, L.P. | |||
| By: | Versant Ventures VII GP-GP, LLC | |||
| Its: | General Partner | |||
| By: | /s/ Xxxxx Xxxxx | |||
| Name: | Xxxxx Xxxxx, Ph.D. | |||
| Title: | Managing Director | |||
| Versant Vantage I, L.P. | ||||
| By: | Versant Vantage I GP, L.P. | |||
| By: | Versant Vantage I GP-GP, LLC | |||
| Its: | General Partner | |||
| By: | /s/ Xxxxx Xxxxx | |||
| Name: | Xxxxx Xxxxx, Ph.D. | |||
| Title: | Managing Director | |||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTOR: | ||||
| ORBIMED PRIVATE INVESTMENTS VIII, LP | ||||
| By: | OrbiMed Capital GP VIII LLC, its General Partner | |||
| By: | OrbiMed Advisors LLC, its Managing Member | |||
| By: | /s/ Xxxxx Xxxxxx | |||
| Name: | Xxxxx Xxxxxx | |||
| Title: | Member | |||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTOR: | ||||
| Redmile Biopharma Investments II, L.P. | ||||
| By: | Redmile Biopharma Investments II (GP), LLC, its general partner | |||
| By: | /s/ Xxxxxx Xxxxxx | |||
| Name: | Xxxxxx Xxxxxx | |||
| Title: | Authorized Signatory | |||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTOR: | ||||
| LIFESCI VENTURE PARTNERS II, LP | ||||
| By: | /s/ Xxxx Xxxx | |||
| Name: | Xxxx Xxxx | |||
| Title: | Managing Member | |||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTOR: | ||||
| ALEXANDRIA VENTURE INVESTMENTS, LLC, a Delaware limited liability company | ||||
| By: | ALEXANDRIA REAL ESTATE EQUITIES, INC., a Maryland corporation, managing member | |||
| By: | /s/ Xxxxx Xxxxxxxx | |||
| Name: | Xxxxx Xxxxxxxx | |||
| Title: | SVP – Venture Counsel | |||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTORS: | ||||
| VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP | ||||
| By: | Viking Global Opportunities Portfolio GP, LLC, its General Partner | |||
| By: | /s/ Xxxxxxxx Xxxxx | |||
| Name: | Xxxxxxxx Xxxxx | |||
| Title: | Authorized Signatory | |||
| VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP | ||||
| By: | Viking Global Opportunities Portfolio GP, LLC, its General Partner | |||
| By: | /s/ Xxxxxxxx Xxxxx | |||
| Name: | Xxxxxxxx Xxxxx | |||
| Title: | Authorized Signatory | |||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
The parties have executed this Third Amended and Restated Investors’ Rights Agreement as of the date first written above.
| INVESTORS: | ||||
| Samsara Biocapital, L.P. | ||||
| By: | Samsara BioCapital GP, LLC, General Partner | |||
| By: | /s/ Xxxxxxxx Xxxxxxxx | |||
| Name: | Xxxxxxxx Xxxxxxxx, M.D., Ph.D. | |||
| Title: | Managing General Partner | |||
| 436, L.P. | ||
| By: | 436 GP, LLC, | |
| General Partner | ||
| By: | /s/ Xxxxxxxx Xxxxxxxx | |
| Name: Xxxxxxxx Xxxxxxxx, M.D., Ph.D. | ||
| Title: Managing Member | ||
Signature Page to Third Amended and Restated Investors’ Rights Agreement
SCHEDULE A
INVESTORS
| Name |
Address |
| ||
| Sofinnova Venture Partners X, L.P. | 0000 Xxxx Xxxx Xxxx, Building 4-Xxxxx 000 Xxxxx Xxxx, XX 00000 Attn: Xxxxxx Xxxxxxxx, Chief Legal Officer |
|||
| Sofinnova Venture Partners XI, L.P. | 0000 Xxxx Xxxx Xxxx, Building 0-Xxxxx 000 Xxxxx Xxxx, XX 00000 Attn: Xxxxxx Xxxxxxxx, Chief Legal Officer |
|||
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | Legal and Compliance 000 Xxxxxxxx Xxxxxx Xxxxxx, XX 00000 Attn: Private Investment Services |
|||
| Sands Capital Life Sciences Pulse Fund II, L.P. | 0000 Xxxxxx Xxxxxxxxx, Xxxxx 0000 Xxxxxxxxx, XX 00000 |
|||
| Xxxxxxx Capital Master Fund Ltd. | C/X Xxxxxxx Capital Management LP. 000 Xxxxxxx Xxxxxx, Xxxxx 0000 Xxx Xxxx, XX 00000 |
|||
| Soleus Private Equity Fund III, L.P. | 000 Xxxxx Xxxxx Xxxx Xxxxxx Xxxxx Xxxxxxxxx, XX 00000 Attention: Xxxxxx X. Xxxxxxxx |
|||
| VENROCK HEALTHCARE CAPITAL PARTNERS EG, L.P. | 0 Xxxxxx Xxxx, 00xx Xxxxx Xxx Xxxx, XX 00000 |
|||
| VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P. | 0 Xxxxxx Xxxx, 00xx Xxxxx Xxx Xxxx, XX 00000 |
|||
| VHCP CO-INVESTMENT HOLDINGS III, LLC | 0 Xxxxxx Xxxx, 00xx Xxxxx Xxx Xxxx, XX 00000 |
|||
| Perceptive Life Sciences Master Fund, Ltd. | 00 Xxxxx Xxxxx, 00xx Xxxxx Xxx Xxxx, XX 00000 |
|||
| Vivo Opportunity Fund, L.P. | C/O: Vivo Capital LLC 000 Xxxxxx Xxxxxx, Xxxx Xxxx, XX 00000 Attn: General Counsel E-mail: Telephone: Fax: |
|||
| Acuta Capital Fund, LP | Acuta Capital Fund, LP c/o: Acuta Capital Partners, LLC 0000 Xxxxxxxx Xxxx, Xxxxx 000 Xxxxxxx, XX 00000 |
|||
| Acuta Opportunity Fund, LP | Acuta Opportunity Fund, LP c/o: Acuta Capital Partners, LLC 0000 Xxxxxxxx Xxxx, Xxxxx 000 Xxxxxxx, XX 00000 |
|||
| Deerfield Partners, L.P. | c/o Deerfield Management Company, L.P. 000 Xxxx Xxxxxx Xxxxx, 00xx Xxxxx Xxx Xxxx, XX 00000 |
|||
| TCG Crossover Fund I, L.P. | c/o TCG Crossover Management, LLC 000 Xxxx Xxxxxx Xxxx Xxxx, XX 00000 Attn: Xxxxx Xxxxxxx |
|||
| venBio Global Strategic Fund III, L.P. | 0000 Xxxxx Xxxxxx, Xxxxx 000 Xxx Xxxxxxxxx, XX 00000 |
|||
| Versant Venture Capital VII, L.P. | Xxx Xxxxxxx Xxxxxx, Xxxxx 0000 Xxx Xxxxxxxxx, XX 00000 |
|||
| Versant Vantage I, L.P. | Xxx Xxxxxxx Xxxxxx, Xxxxx 0000 Xxx Xxxxxxxxx, XX 00000 |
|||
| RYZB Holdings Limited
Copies to be delivered to: Xxxxxxx Procter |
89 Nexus Way Camana Bay P.O. Box 31106 Grand Cayman KY1-1205 Cayman Islands
The New York Times Building 000 Xxxxxx Xxxxxx Xxx Xxxx, XX 00000 Xxxxxx Xxxxxx |
|||
| OrbiMed Private Investments VIII, LP | 000 Xxxxxxxxx Xxxxxx, 00xx Xxxxx Xxx Xxxx, XX 00000 |
|||
| Redmile Biopharma Investments II, L.P. | Xxx Xxxxxxxxx Xxxxx, Xxxxx X0-000 Xxx Xxxxxxxx, Xxx Xxxxxxxxx, XX 00000 |
|||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | c/o Viking Global Investors LP 00 Xxxxxxxx Xxxxxx Xxxxxxxxx, XX 00000 Attention: General Counsel |
|||
| Viking Global Opportunities Drawdown (Aggregator) LP | c/o Viking Global Investors LP 00 Xxxxxxxx Xxxxxx Xxxxxxxxx, XX 00000 Attention: General Counsel |
|||
| Logos Opportunities Fund II, L.P. | 0 Xxxxxxxxx Xxxxx Xxxxxxxx X, Xxxxx X0-000 Xxx Xxxxxxxxx, XX 00000 |
|||
| Samsara Biocapital, L.P. | 000 Xxxxxxxxxxx Xxxx Xxxx Xxxx, XX 00000 |
|||
| 436, L.P. | 000 Xxxxxxxxxxx Xxxx Xxxx Xxxx, XX 00000 |
|||
| Cormorant Private Healthcare Fund III, LP | 000 Xxxxxxxxx Xxxxxx 00xx Xxxxx Xxxxxx, XX 00000 |
|||
| Cormorant Global Healthcare Master Fund, LP | 000 Xxxxxxxxx Xxxxxx 00xx Xxxxx Xxxxxx, XX 00000 |
|||
| CRMA SPV, L.P. | 000 Xxxxxxxxx Xxxxxx 00xx Xxxxx Xxxxxx, XX 00000 |
|||
| LifeSci Venture Partners II, LP | 000 Xxxx 00xx Xxxxxx, 00xx Xxxxx Xxx Xxxx, XX 00000 |
|||
| Alexandria Venture Investments, LLC | 00 X. Xxxxxx Xxx Xxxxxxxx, XX 00000 |
|||
| Xxxx X Xxxxxxxxxxx Trust | 000 Xxx Xxxxxxx Xxxxx Xxxxxxx, XX 00000 |
|||
| Xxxx Xxxxx | 000 Xxxxxxx Xxxxxx Xx Xxxxx, XX 00000 |
|||
| Xxxx Xxxxxxx Family Trust | 000 Xxxxx Xxx Xxxxxxxx, XX 00000 |
|||
| ARTICLE 4 TRUST UNDER XXXXXXX X. XXX APPOINTMENT TRUST | 00 Xxxxxxxxx Xxxx, Xxx XX0 Xxx Xxxx, XX 00000 |
|||
| ARTICLE 4 TRUST UNDER XXXXXXXX X. XXX APPOINTMENT TRUST | 00 Xxxxxxxxx Xxxx, Xxx XX0 Xxx Xxxx, XX 00000 |
|||
| ARTICLE 4 TRUST UNDER XXXXXXX XXX APPOINTMENT TRUST | 00 Xxxxxxxxx Xxxx, Xxx XX0 Xxx Xxxx, XX 00000 |
|||
| ABG WTT-Rayzebio Limited | c/o Unit 3002-3004, 30/F., Gloucester Tower, The Landmark 00 Xxxxx’x Xxxx Xxxxxxx, Xxxx Xxxx Attn: Wing C Xxx |
|||
| Xx Xxxxxx Holding LLC | c/o Qatar Investment Authority Ooredoo Tower (Building 00) Xx Xxxxx Xxxxxx (Street 801) Al Dafna (Zone 61) Doha, Qatar
Attention: Xxxxxxx Xxxx Xxxxxx, MD, Executive Director, Healthcare, and Xxxxxxx XxXxxxx, Chief, |
|||
| Investment Execution
With copies (which shall not constitute notice) to:
General Counsel Qatar Investment Authority Ooredoo Tower (Building 00) Xx Xxxxx Xxxxxx (Street 801) Al Dafna (Zone 61) Doha, Qatar
A copy (which shall not constitute notice) shall also be sent to:
Shearman & Sterling LLP 000 Xxxxxxx Xxxxxx, 00xx Xxxxx Xxx Xxxxxxxxx, XX 00000 Attn: Xxxxxxx X. Xxxx |
